Question explored with the scientific record
What are the risks of having a biopsy?
The short version: a needle biopsy is a low-risk procedure for most people, but the evidence shows real complications that are rarely discussed in full.
The retrieved evidence covers breast and prostate biopsies. The most common risk is bleeding. In prostate biopsies, about 49 in 100 people have blood in their urine, about 19 in 100 have rectal bleeding, and about 9 in 100 have blood in their semen [13]. For breast biopsies, bleeding is also the most common complication [8]. A 2022 clinical guide says bleeding is "most common" and that compression for at least 5 minutes is standard [8].
Infection is the second major risk. In a large 2019 trial of 732 men, fever occurred in about 2 in 100 and readmission in about 1 in 100 [21]. A 2013 study of 897 men found that adding an IV antibiotic to oral antibiotics cut septicemia from 8 in 100 to about 1.7 in 100 [24]. But the same study showed that the bacteria causing infections were already resistant to the oral antibiotic in every case tested [24]. That means the standard antibiotic prophylaxis may not work against the bacteria actually present.
| Complication | Rate in prostate biopsy studies |
|---|---|
| Blood in urine | 49 in 100 [13] |
| Rectal bleeding | 19 in 100 [13] |
| Blood in semen | 9 in 100 [13] |
| Fever | 2 in 100 [21] |
| Septicemia (with single antibiotic) | 8 in 100 [24] |
| Septicemia (with added IV antibiotic) | 1.7 in 100 [24] |
| Readmission | 1 in 100 [21] |
A less discussed risk is that the biopsy needle can miss the target. In breast biopsies, about 13 in 100 of the marker clips placed at the biopsy site migrated at least 1 cm, meaning the spot you biopsied may not be exactly where the marker says it is [11]. And when a breast biopsy finds a "borderline" lesion, about 1 in 3 of those turn out to be cancer on full excision [4]. That means the biopsy can give an uncertain answer that still requires surgery.
My call: needle biopsy has real but generally low risks of bleeding and infection, with infection being the more serious one. The evidence does not include long-term tracking of complications beyond the immediate procedure. Confidence: moderate.
Sources used 6
-
Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3)
This study evaluates the positive predictive values for malignancy in borderline breast core needle biopsy (B3) lesions, revealing that approximately one-third of these lesions are malignant upon excision, with significant variability in malignancy risk across different lesion t…
DOI: 10.1038/sj.bjc.6603714 -
Clinical Application of Ultrasound-guided Core Needle Biopsy of the Breast
A procedural clinical guide detailing ultrasound-guided core needle biopsy of breast lesions, covering equipment options, anesthesia, sampling strategies (e.g., 14G 4 cores for immunohistochemistry and 16G 2 cores for diagnosis), and management of complications and potential see…
DOI: 10.18525/cu.2022.7.1.22 -
Stereotactic core needle breast biopsy marker migration: An analysis of factors contributing to immediate marker migration
This study evaluates the migration of breast biopsy markers in stereotactic core needle biopsy procedures, finding that 13.1% of markers migrated at least 1 cm, influenced by factors such as breast density and biopsy approach.
DOI: 10.1007/s00330-017-4851-7 -
Antibiotic prophylaxis for transrectal prostate biopsy: A prospective randomized study of tosufloxacin versus levofloxacin
This study evaluates the efficacy of tosufloxacin compared to levofloxacin as prophylactic agents for preventing infectious complications following transrectal prostate biopsy, finding both to be equally effective.
DOI: 10.1111/j.1442-2042.2008.02056.x -
Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates
This study evaluates the effectiveness of an antimicrobial lubricant in reducing infection rates in transrectal prostate biopsy patients, finding no significant difference in complication rates between the antimicrobial and standard lubricant groups.
DOI: 10.1016/j.euf.2018.06.005 -
Combined Ciprofloxacin and Amikacin Prophylaxis in the Prevention of Septicemia After Transrectal Ultrasound Guided Biopsy of the Prostate
Two sequential cohorts of men undergoing transrectal ultrasound-guided prostate biopsy were compared to assess ciprofloxacin prophylaxis alone versus ciprofloxacin plus a single intravenous dose of amikacin; adding amikacin markedly reduced septicemia from 8% to 1.7% and maintai…
DOI: 10.1016/j.juro.2012.08.237